paroxetine + lithium

Paroxetine + lithium is a combination therapy involving two distinct pharmaceutical agents—paroxetine, a selective serotonin reuptake inhibitor (SSRI) antidepressant, and lithium, a mood stabilizer. This combination is primarily used in the management of treatment-resistant depression and bipolar disorder, particularly when depressive episodes do not respond to monotherapy. Paroxetine acts by inhibiting the sodium-dependent serotonin transporter, thereby increasing synaptic serotonin levels. Lithium’s mechanism involves modulation of neurotransmitter release and second messenger systems in the brain. The combination can increase serotonergic activity but carries an increased risk for adverse effects such as serotonin syndrome and additive central nervous system depression; therefore, it should be used with caution under close medical supervision[2][3][4][7].